路德生物环保科技股份有限公司 证券代码：688156 证券简称：路德环境 公告编号：2025-004 路德生物环保科技股份有限公司 第四届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 路德生物环保科技股份有限公司（以下简称"公司"）第四届董事会第二十 三次会议于 2025 年 4 月 17 日在公司会议室以现场与通讯表决相结合的方式召开， 本次会议会议通知已于 2025 年 4 月 7 日以电子邮件的方式发出。本次会议应出席 董事 7 名，实到 7 名，本次会议由董事长季光明先生主持。会议的召集、召开和 表决情况符合《中华人民共和国公司法》（以下简称"《公司法》"）等有关法 律、法规及《路德生物环保科技股份有限公司章程》（以下简称"公司章程"） 的规定，形成的决议合法、有效。 二、董事会会议审议情况 参会董事逐项审议并以投票表决方式通过了下列议案： （一）审议通过《关于 2024 年年度报告及其摘要的议案》 具体内容详见同日刊登在上海证券交易所网站（www.sse.c ...

Financial Performance - The company reported a net loss attributable to shareholders of 56,551,531.55 yuan for the year 2024, with the parent company recording a net loss of 45,353,831.06 yuan[7]. - The company's operating revenue for 2024 was CNY 277,618,726.54, a decrease of 20.92% compared to CNY 351,076,211.54 in 2023[24]. - The net profit attributable to shareholders for 2024 was a loss of CNY 56,551,531.55, representing a decline of 309.69% from a profit of CNY 26,969,532.97 in 2023[24]. - Basic and diluted earnings per share for 2024 were both -CNY 0.56, reflecting a 300% decline from CNY 0.28 in 2023[25]. - The company's net assets attributable to shareholders decreased by 6.97% to CNY 834,367,357.99 at the end of 2024, compared to CNY 896,893,683.89 at the end of 2023[24]. - The company has not achieved profitability since its listing[4]. - The company recorded a non-operating income of 3.12 million yuan, significantly lower than the previous year's 65.06 million yuan[35]. - The company's investment income plummeted by 70.11% to ¥657,274, mainly due to reduced returns from structured financial products[150]. Governance and Compliance - The board of directors has proposed not to distribute profits for the year 2024, which includes no cash dividends, no bonus shares, and no capital reserve conversion[7]. - The audit report issued by Da Xin Accounting Firm confirmed the financial statements as true, accurate, and complete[6]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures regarding external guarantees[11]. - The company has not reported any special arrangements in corporate governance[9]. - All board members attended the board meeting, ensuring collective decision-making[5]. - The company held one annual and one extraordinary shareholders' meeting in 2024, ensuring compliance with relevant laws and regulations[198]. Risks and Challenges - The company has described potential risks in the report, which investors should be aware of when considering future investments[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a commitment to investors[8]. - The company faces risks related to industry downturns and increased competition, which could negatively impact production and operations if demand decreases[130]. - The company faces risks related to the mismatch between new production capacity and market expansion[134]. Research and Development - The company has developed a core technology system for organic residue microbial solid-state fermentation, which has received multiple awards including the second prize for scientific and technological progress in Sichuan Province[24]. - The company has increased its R&D team to 51 members, accounting for 8.95% of the total workforce, with a focus on enhancing technical capabilities in synthetic biology and enzyme engineering[52]. - Research and development (R&D) expenses amounted to ¥19,759,033.83, representing a 44.70% increase compared to the previous year[112]. - R&D expenses accounted for 7.12% of total revenue, an increase of 3.23 percentage points from the previous year[112]. - The company has published two SCI papers on enzyme engineering and fermentation technology, showcasing its advancements in research and development[54]. - The company is leveraging AI technology to innovate in enzyme modification, significantly improving the efficiency of biological conversion processes[98]. - The company is focusing on the development of new feed based on microbial engineering to ensure food security and achieve agricultural carbon neutrality[101]. Market and Product Development - The company is focused on expanding its market presence and enhancing its product offerings, including functional feed materials derived from organic waste[24]. - The company achieved operating revenue of CNY 277.62 million, a decrease of 20.92% compared to the same period last year[26]. - The sales volume of the company's liquor lees biological fermentation feed business reached 112,600 tons, an increase of 20.74% year-on-year, with sales revenue of CNY 216.85 million, up 10.19% year-on-year[26]. - The revenue from the biological fermentation feed business was 216.85 million yuan, an increase of 10.19%, accounting for 78.11% of total operating revenue[43]. - The company plans to enhance the scale effect of its liquor lees biological fermentation feed business as new projects are put into operation, which is expected to gradually reduce the impact of period expenses on profits[30]. - The company has developed innovative products such as "善水路德®酵肽" and "蔺福®" series, enhancing nutritional and functional components for animal feed while addressing environmental concerns[63]. - The company is actively pursuing new strategies for growth, including potential mergers and acquisitions to enhance its technological capabilities and market reach[24]. Environmental and Sustainability Initiatives - The company is committed to reducing antibiotic usage by 30-50% and lowering nitrogen and phosphorus emissions through its microbial fermentation technology[99]. - The company’s fermentation feed services align with national policies focused on sustainable growth and environmental protection, supporting the circular economy in the liquor industry[75]. - The company has developed a technology for the resource utilization of high-concentration brewing wastewater, producing liquid fermentation feed while addressing high treatment costs and environmental concerns[76]. - The company is focused on the high-value utilization of brewing by-products, with ongoing projects aimed at producing γ-PGA and GABA, which are expected to fill domestic production gaps[117]. - The company aims to enhance its market share and brand image by focusing on biomanufacturing and expanding its production capacity in the coming years[92]. Financial Management and Strategy - The company has implemented strict cost control measures, including long-term agreements with liquor companies to stabilize procurement costs[128]. - The company has enhanced its accounts receivable management by linking collection efforts to departmental performance evaluations, improving cash flow efficiency[57]. - The company will implement a centralized budget management system to optimize operational costs and ensure stable cash flow[193]. - The company plans to invest in projects that convert organic waste (such as liquor dregs) into fermentation feed through biotechnology, leveraging policy benefits[184]. - The company aims to integrate the liquor industry with the breeding industry, creating an innovative industrial chain model focused on high-value utilization of brewing waste[184].

Financial Performance - The company's revenue for Q1 2025 was CNY 63.07 million, a decrease of 7.18% compared to the same period last year[3]. - Net profit attributable to shareholders was CNY 1.25 million, down 77.89% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 0.72 million, a decrease of 85.75%[5]. - The cash flow from operating activities was CNY 9.46 million, a decline of 72.10% compared to the previous year[3]. - Total revenue for Q1 2025 was CNY 63,074,491.09, a decrease of 7.5% compared to CNY 67,954,689.05 in Q1 2024[19]. - Operating profit for Q1 2025 was a loss of CNY 3,558,033.24, compared to a profit of CNY 4,506,061.18 in Q1 2024[20]. - Net profit for Q1 2025 was CNY 213,477.84, significantly down from CNY 4,072,055.93 in Q1 2024[20]. - The company reported a significant increase in financial expenses, with interest expenses rising to CNY 4,921,381.45 from CNY 2,491,696.45 year-over-year[19]. - Basic and diluted earnings per share were both ¥0.01, down from ¥0.06 in the previous year[21]. - The total comprehensive income attributable to the parent company was ¥1,254,440.92, compared to ¥5,673,773.52 in the previous period[21]. Assets and Liabilities - The company reported a total asset value of CNY 1.70 billion, a decrease of 1.73% from the end of the previous year[4]. - Total assets decreased to CNY 1,695,470,741.28 from CNY 1,725,397,885.37 year-over-year[18]. - Total liabilities decreased to CNY 802,384,692.71 from CNY 852,525,314.64 year-over-year[17]. - Current liabilities totaled CNY 450,538,735.26, down from CNY 540,351,071.06 in the previous year[17]. - Non-current liabilities increased to CNY 351,845,957.45 from CNY 312,174,243.58 year-over-year[17]. Cash Flow - The net cash flow from operating activities was -72.10 million RMB, attributed to decreased cash received from sales and increased salary and tax expenses[10]. - The net cash flow from investing activities was -33.16 million RMB, mainly due to reduced cash payments for fixed assets and other long-term assets[10]. - The net cash flow from financing activities was -84.62 million RMB, resulting from reduced bank loans and timely repayment of maturing loans[10]. - In Q1 2025, the company reported a net cash flow from operating activities of ¥9,457,776.71, a decrease of 72% compared to ¥33,903,191.43 in Q1 2024[23]. - Total cash inflow from operating activities was ¥106,635,040.51, down 25% from ¥142,027,261.14 in the previous year[23]. - The company experienced a significant decline in cash received from sales, totaling ¥70,739,702.15, which is a 36% decrease from ¥109,982,009.24 in Q1 2024[23]. - The net cash flow from investing activities was -¥88,268,459.07, an improvement from -¥132,056,910.68 in Q1 2024[24]. - Cash inflow from financing activities was ¥88,974,000.00, a decrease of 39% from ¥147,170,000.00 in Q1 2024[25]. - The ending cash and cash equivalents balance was ¥147,088,067.86, down from ¥183,280,770.50 in Q1 2024[25]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 3,090[12]. - The largest shareholder, Ji Guangming, holds 27.70% of the shares, totaling 27,897,730 shares[13]. - There were no changes in the participation of major shareholders in margin trading or securities lending activities[14]. Business Operations - Research and development expenses totaled CNY 2.21 million, down 32.85% year-on-year, accounting for 3.51% of revenue[4]. - The sales volume of the company's liquor lees fermentation feed business reached 27,500 tons, an increase of 12.16% year-on-year, but revenue from this segment decreased by 7.38% to CNY 46.61 million[5]. - Revenue from inorganic solid waste treatment services increased by 22.35% to CNY 13.33 million, recovering from a low operating rate in the previous year[5]. - The company plans to improve the gross margin of its liquor lees fermentation feed business by optimizing raw material procurement and increasing production capacity utilization[5]. - The company experienced a decline in gross profit margin in its liquor residue fermentation feed business due to price adjustments and industry factors[10]. - The company has not disclosed any significant new strategies or product developments during the reporting period[15].

路德生物环保科技股份有限公司 证券代码：688156 证券简称：路德环境 公告编号：2025-007 路德生物环保科技股份有限公司 关于 2024 年度拟不进行利润分配的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次拟不进行利润分配的预案已经公司第四届董事会第二十三次会议、 第四届监事会第十九次会议审议通过，尚需提交公司 2024 年年度股东大会审议。 公司不触及《上海证券交易所科创板股票上市规则》（以下简称"《股 票上市规则》"）第 12.9.1 条第一款第（八）项规定的可能被实施其他风险警 示的情形。 一、2024 年度利润分配方案基本情况 （一）利润分配方案的具体内容 经大信会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属于上 市公司股东的净利润为-56,551,531.55 元，母公司实现净利润-45,353,831.06 元。截至 2024 年 12 月 31 日，公司合并报表未分配利润为 137,202,171.22 元， 母公司未分配利润为 92,198,965.12 ...

路德环境公告，2025年第一季度营业收入6307.45万元，同比下降7.18%。净利润125.44万元，同比下降 77.89%。 ...

路德环境公告，2024年营业收入为2.78亿元，同比下降20.92%。归属于上市公司股东的净亏损5655.15 万元，去年同期净利润2696.95万元。公司2024年度拟不进行利润分配，不派发现金红利，不送红股， 不以资本公积转增股本和其他形式的分配。 ...

国投证券股份有限公司 关于路德生物环保科技股份有限公司 部分募投项目结项及部分募投项目延期的核查意见 国投证券股份有限公司（以下简称"国投证券"或"保荐机构"，曾用名为 安信证券股份有限公司）作为路德生物环保科技股份有限公司（简称"路德环境" 或"公司"）的保荐机构和持续督导机构，根据《上市公司监管指引第2号—— 上市公司募集资金管理和使用的监管要求》《上海证券交易所上市公司自律监管 指引第1号——规范运作》《上海证券交易所科创板股票上市规则》等相关规定， 对路德环境部分募投项目结项及部分募投项目延期事项进行审慎核查，具体核查 情况和核查意见如下： 一、募集资金基本情况 （一）募集资金金额及到账时间 经中国证券监督管理委员会《关于同意路德环境科技股份有限公司首次公开 发行股票注册的批复》（证监许可[2020]1915 号）核准，并经上海证券交易所同 意，公司首次向社会公开发行人民币普通股股票 2,296 万股，发行价格为每股 15.91 元，募集资金总额为 36,529.36 万元，根据相关规定扣除发行费用 4,111.88 万元后实际募集资金净额为 32,417.48 万元。其中，保荐承销费用为 2,922 ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Composite Index (000680) increased by 0.61% as of April 14, 2025, with notable gains from stocks such as Yuyuan Pharmaceutical (688658) up 19.91%, and Kexing Pharmaceutical (688136) up 16.90% [1] - The Penghua Sci-Tech Innovation Index ETF (589680) rose by 0.76%, marking its fifth consecutive increase, indicating a strong performance in the AI industry chain [2] - The top ten weighted stocks in the Sci-Tech Innovation Board Composite Index as of March 31, 2025, include Haiguang Information (688041) and Cambrian (688256), collectively accounting for 22.34% of the index [3] Group 2 - The AI industry chain is experiencing breakthroughs, with expectations for major product releases from companies like Alibaba and Tencent around May to June [2] - The Chinese government is likely to enhance policy support and funding for the technology sector, particularly in AI, as part of its strategy to counterbalance the U.S. in the ongoing trade disputes [2]

Core Viewpoint - The article discusses the recent performance of the STAR Market Composite Index and highlights the impact of U.S.-China trade policies on the pharmaceutical sector, suggesting potential investment opportunities in innovation, overseas markets, equipment upgrades, and consumer recovery [3][4]. Group 1: Market Performance - As of April 14, 2025, the STAR Market Composite Index rose by 1.13%, with notable increases in stocks such as Yuyuan Pharmaceutical (up 19.99%) and Kexing Pharmaceutical (up 17.23%) [3]. - The STAR Market ETF (Hua Xia) also saw a rise of 1.19%, marking its fifth consecutive increase, with a latest price of 0.94 yuan [3]. - The trading volume for the STAR Market ETF was active, with a turnover rate of 23.24% and a transaction value of 197 million yuan [3]. Group 2: Trade Policy Impact - Following the U.S. government's announcement of a 34% tariff on Chinese goods on April 2, 2025, both countries adjusted their bilateral trade tariffs to 125% as of April 11, 2025 [3]. - The frequent adjustments in tariff policies are expected to disrupt U.S.-China pharmaceutical trade, but companies primarily exporting to markets outside the U.S. may be less affected [3]. - The increased tariffs on U.S. goods could accelerate the import substitution process for high-market-share biopharmaceutical products in China [3]. Group 3: Investment Themes - The report suggests focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [4]. - The "innovation" theme emphasizes investing in globally competitive innovative drugs and promising categories with significant market potential [4]. - The "overseas expansion" theme indicates that there are long-term opportunities in overseas markets [4]. - The "equipment upgrades" theme anticipates increased support for medical equipment updates from central and local government financing [4]. - The "consumer recovery" theme highlights potential rebounds in sectors like ophthalmology, dentistry, and medical aesthetics due to consumer stimulus policies [4]. Group 4: ETF Performance and Metrics - The STAR Market ETF (Hua Xia) has reached a new high in scale at 839 million yuan and a new high in shares at 908 million [4]. - Recent net inflows into the ETF totaled approximately 22.08 million yuan, with a total of 57.84 million yuan net inflow over the past five trading days [4]. - The ETF's management fee is 0.15%, and the custody fee is 0.05%, which are among the lowest in comparable funds [5]. - The tracking error for the ETF over the past month is 0.010%, indicating high tracking precision compared to similar funds [5]. Group 5: Valuation Insights - The latest price-to-earnings ratio (PE-TTM) for the STAR Market Composite Index is 129.12, which is at a historical low, being in the 19.67th percentile over the past year [6]. - The top ten weighted stocks in the STAR Market Composite Index account for 22.34% of the index, with companies like Haiguang Information and Cambricon Technologies among the leaders [6].

4月8日，路德环境(688156)股价强势涨停，收盘报14.39元/股，涨幅达20%，日振幅值达19.27%，日换 手率9.57%，成交额1.34亿元，总市值升至14.49亿元。 为把握政策机遇，路德环境加速布局产能，先后建成投产了5个白酒糟生物发酵饲料工厂，包括古蔺路 德、金沙路德、亳州路德、遵义路德、永乐路德。目前公司白酒糟生物发酵饲料业务总产能达到52万 吨。 针对市场波动，路德环境相关负责人向证券时报记者表示，近期美国政府加征"对等关税"政策可能推高 大豆远期价格，而公司研发的白酒糟生物发酵饲料产品可有效替代豆粕和玉米，既符合国家节粮政策导 向，又为粮食安全提供保障。 2024年12月，路德环境连续发布公告，遵义路德引入湖北农发饲料有限公司作为战略股东，农发饲料将 以现金方式向遵义路德增资并签订长期生物发酵饲料大额采购订单；金沙路德引入贵州省生态环保发展 股权投资基金3200万元增资，进一步加码产能建设。 当日，沪深交易所公布的龙虎榜数据显示，路德环境因单日涨幅超过15%上榜，总买入额3861.10万 元，总卖出额3128.28万元，总净买732.82万元。 路德环境相关负责人表示，随着项目的陆续建成 ...